Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Klinic vs Omnia TeleHealth

Klinic
Graded #313

Higher grade

vs+4.599999999999994
Omnia TeleHealth
Graded #419

Lower grade

The verdict

Klinic takes it — 60.8/100 to 56.2/100.

Klinic grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Klinic is a LegitScript-certified multi-condition telehealth platform prescribing brand-name GLP-1 medications—Wegovy (semaglutide) and Zepbound (tirzepatide)—to patients across all 50 U.S.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
45
45
Dose & formulationKlinic +13
53
40
Clinical oversightOmnia TeleHealth +1
79
80
Labs & monitoringKlinic +3
64
61
FulfillmentKlinic +14
76
62
Contract termsEven
55
55
Klinic · left barOmnia TeleHealth · right bar

The numbers

MetricKlinicOmnia TeleHealth
WeighScore60.8/10056.2/100
GradeCC
Scorecard rank#313#419
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Klinic

Graded #313 · C

Strengths

  • LegitScript certified, licensed in all 50 states, DEA registered, HIPAA/SOC 2 Type II compliant
  • Broad insurance acceptance including Medicare, Medicaid, BCBS, Aetna, Cigna, UHC, and Humana
  • Klinic handles all prior authorization—patient never manages PA paperwork
  • Brand-name FDA-approved GLP-1s (Wegovy, Zepbound) at full clinical doses with home delivery
  • Named clinical leadership (CMO Dr. Saba Haq, Chief Physician Dr. Vivek Chander) and disclosed founder

Where it loses points

  • Brand-name meds are costly self-pay: Wegovy ~$499/month, Zepbound ~$299/month (med cost alone; consult extra)
  • No compounded semaglutide or tirzepatide option for patients seeking lower-cost alternatives
  • Medication cost is separate from visit fees ($99 initial, $75 follow-up) — total self-pay cost is higher
  • No labs or dedicated nutrition/coaching program included in any plan
  • Pharmacy fulfillment via Klinic Pharmacy Hub Services LLC (non-dispensing hub); actual dispensing is third-party
Omnia TeleHealth

Graded #419 · C

Strengths

  • LegitScript-certified; DNP-led by Blair Carmichael-Lober with 10+ years clinical experience
  • $69 flat consult fee — no insurance, no surprise bills; works with Belmar Pharma for compounded GLP-1
  • Both semaglutide and tirzepatide available; compounded options via Belmar at lower cost than brand
  • Weight loss visits include nutrition guidance, exercise recommendations, and behavioral coaching
  • Prescriptions sent to any pharmacy nationwide or coordinated through Belmar Pharma Solutions

Where it loses points

  • Only 17 states — specific states not publicly disclosed; must call (251) 220-8875 to confirm
  • Medication pricing is gated — not published on website; contact required for compounded GLP-1 cost
  • No labs mentioned or included — baseline bloodwork protocol not published on any page
  • Medication cost is a separate pharmacy bill; the $69 visit fee covers consult only
  • Smaller platform with limited public track record vs. larger national GLP-1 telehealth providers

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard